View Financial HealthHyosungONBCo.Ltd 배당 및 자사주 매입배당 기준 점검 0/6HyosungONBCo.Ltd 현재 배당금을 지급하지 않습니다.핵심 정보0%배당 수익률0%자사주 매입 수익률총 주주 수익률0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향0%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Jun 22Upcoming dividend of ₩100.00 per share at 1.1% yieldEligible shareholders must have bought the stock before 29 June 2023. Payment date: 12 October 2023. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.2%). Lower than average of industry peers (1.5%).Upcoming Dividend • Jun 22Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 June 2021. Payment date: 15 October 2021. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (2.1%). Lower than average of industry peers (1.4%).모든 업데이트 보기Recent updates공고 • 13hHyosungONBCo.,Ltd, Annual General Meeting, Sep 29, 2026HyosungONBCo.,Ltd, Annual General Meeting, Sep 29, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 46, yuseong-daero 1596beon-gil, yuseong-gu, daejeon South KoreaValuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩4,185, the stock trades at a trailing P/E ratio of 51.1x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total loss to shareholders of 47% over the past three years.Buy Or Sell Opportunity • Jun 12Now 22% overvaluedOver the last 90 days, the stock has fallen 21% to ₩5,180. The fair value is estimated to be ₩4,260, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 14% over the last 3 years. Earnings per share has declined by 8.4%.Reported Earnings • Feb 22Second quarter 2026 earnings released: ₩60.00 loss per share (vs ₩100.00 profit in 2Q 2025)Second quarter 2026 results: ₩60.00 loss per share (down from ₩100.00 profit in 2Q 2025). Revenue: ₩4.22b (down 32% from 2Q 2025). Net loss: ₩472.0m (down 160% from profit in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.New Risk • Feb 22New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 33% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.2% net profit margin). Market cap is less than US$100m (₩49.2b market cap, or US$34.0m).New Risk • Nov 29New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 12% Last year net profit margin: 17% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (12% net profit margin). Market cap is less than US$100m (₩48.1b market cap, or US$32.8m).분석 기사 • Sep 23Some Investors May Be Willing To Look Past HyosungONBCo.Ltd's (KOSDAQ:097870) Soft EarningsThe market for HyosungONBCo.,Ltd's ( KOSDAQ:097870 ) shares didn't move much after it posted weak earnings recently...Reported Earnings • Sep 18Full year 2025 earnings released: EPS: ₩354 (vs ₩548 in FY 2024)Full year 2025 results: EPS: ₩354 (down from ₩548 in FY 2024). Revenue: ₩24.4b (down 13% from FY 2024). Net income: ₩2.81b (down 37% from FY 2024). Profit margin: 12% (down from 16% in FY 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.공고 • Aug 15HyosungONBCo.,Ltd, Annual General Meeting, Sep 29, 2025HyosungONBCo.,Ltd, Annual General Meeting, Sep 29, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 46, yuseong-daero 1596beon-gil, yuseong-gu, daejeon South KoreaValuation Update With 7 Day Price Move • Apr 04Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩6,250, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total loss to shareholders of 53% over the past three years.분석 기사 • Mar 28HyosungONBCo.Ltd's (KOSDAQ:097870) Returns On Capital Are Heading HigherWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...Reported Earnings • Feb 20Second quarter 2025 earnings released: EPS: ₩100.00 (vs ₩273 in 2Q 2024)Second quarter 2025 results: EPS: ₩100.00 (down from ₩273 in 2Q 2024). Revenue: ₩6.21b (down 18% from 2Q 2024). Net income: ₩788.5m (down 65% from 2Q 2024). Profit margin: 13% (down from 30% in 2Q 2024). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.New Risk • Jan 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩54.6b market cap, or US$37.8m).분석 기사 • Jan 03Why Investors Shouldn't Be Surprised By HyosungONBCo.,Ltd's (KOSDAQ:097870) 28% Share Price SurgeHyosungONBCo.,Ltd ( KOSDAQ:097870 ) shares have had a really impressive month, gaining 28% after a shaky period...New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩59.0b market cap, or US$41.1m).Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improves as stock rises 44%After last week's 44% share price gain to ₩7,480, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total loss to shareholders of 5.3% over the past three years.분석 기사 • Sep 26HyosungONBCo.Ltd's (KOSDAQ:097870) Profits May Not Reveal Underlying IssuesThe recent earnings posted by HyosungONBCo.,Ltd ( KOSDAQ:097870 ) were solid, but the stock didn't move as much as we...Reported Earnings • Sep 20Full year 2024 earnings released: EPS: ₩548 (vs ₩155 in FY 2023)Full year 2024 results: EPS: ₩548 (up from ₩155 in FY 2023). Revenue: ₩28.1b (down 5.4% from FY 2023). Net income: ₩4.49b (up 255% from FY 2023). Profit margin: 16% (up from 4.3% in FY 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.공고 • Aug 15HyosungONBCo.,Ltd, Annual General Meeting, Sep 27, 2024HyosungONBCo.,Ltd, Annual General Meeting, Sep 27, 2024, at 10:00 Tokyo Standard Time. Location: conference room, 46, yuseong-daero 1596beon-gil, yuseong-gu, daejeon South Korea분석 기사 • Aug 06Is HyosungONBCo.Ltd (KOSDAQ:097870) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩5,860, the stock trades at a trailing P/E ratio of 9.2x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 52% over the past three years.Reported Earnings • Feb 19Second quarter 2024 earnings released: EPS: ₩273 (vs ₩106 in 2Q 2023)Second quarter 2024 results: EPS: ₩273 (up from ₩106 in 2Q 2023). Revenue: ₩7.53b (up 29% from 2Q 2023). Net income: ₩2.24b (up 159% from 2Q 2023). Profit margin: 30% (up from 15% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has fallen by 2% per year.Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩8,400, the stock trades at a trailing P/E ratio of 41x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 10% over the past three years.Reported Earnings • Nov 19First quarter 2024 earnings released: ₩48.00 loss per share (vs ₩98.00 loss in 1Q 2023)First quarter 2024 results: ₩48.00 loss per share (improved from ₩98.00 loss in 1Q 2023). Revenue: ₩3.47b (up 17% from 1Q 2023). Net loss: ₩393.2m (loss narrowed 51% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 21Full year 2023 earnings released: EPS: ₩155 (vs ₩464 in FY 2022)Full year 2023 results: EPS: ₩155 (down from ₩464 in FY 2022). Revenue: ₩29.7b (down 13% from FY 2022). Net income: ₩1.27b (down 67% from FY 2022). Profit margin: 4.3% (down from 11% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Upcoming Dividend • Jun 22Upcoming dividend of ₩100.00 per share at 1.1% yieldEligible shareholders must have bought the stock before 29 June 2023. Payment date: 12 October 2023. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.2%). Lower than average of industry peers (1.5%).Reported Earnings • May 18Third quarter 2023 earnings released: EPS: ₩66.00 (vs ₩105 in 3Q 2022)Third quarter 2023 results: EPS: ₩66.00 (down from ₩105 in 3Q 2022). Revenue: ₩9.05b (down 4.6% from 3Q 2022). Net income: ₩542.4m (down 37% from 3Q 2022). Profit margin: 6.0% (down from 9.1% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩9,540, the stock trades at a trailing P/E ratio of 25x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 59% over the past three years.Reported Earnings • Feb 19Second quarter 2023 earnings released: EPS: ₩106 (vs ₩165 in 2Q 2022)Second quarter 2023 results: EPS: ₩106 (down from ₩165 in 2Q 2022). Revenue: ₩5.83b (down 11% from 2Q 2022). Net income: ₩864.6m (down 37% from 2Q 2022). Profit margin: 15% (down from 21% in 2Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 19First quarter 2023 earnings released: ₩98.00 loss per share (vs ₩37.00 loss in 1Q 2022)First quarter 2023 results: ₩98.00 loss per share (further deteriorated from ₩37.00 loss in 1Q 2022). Revenue: ₩2.96b (down 26% from 1Q 2022). Net loss: ₩806.3m (loss widened 159% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩8,190, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 10% over the past three years.Reported Earnings • Sep 23Full year 2022 earnings released: EPS: ₩464 (vs ₩306 in FY 2021)Full year 2022 results: EPS: ₩464 (up from ₩306 in FY 2021). Revenue: ₩34.0b (up 13% from FY 2021). Net income: ₩3.86b (up 62% from FY 2021). Profit margin: 11% (up from 7.9% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩12,100, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 73% over the past three years.Valuation Update With 7 Day Price Move • Jul 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩9,270, the stock trades at a trailing P/E ratio of 25.4x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 19% over the past three years.Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₩12,150, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 37% over the past three years.Reported Earnings • May 22Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: EPS: ₩105 (up from ₩98.00 in 3Q 2021). Revenue: ₩9.49b (up 16% from 3Q 2021). Net income: ₩863.1m (up 16% from 3Q 2021). Profit margin: 9.1% (in line with 3Q 2021). Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 19%. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩11,950, the stock trades at a trailing P/E ratio of 34x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 42% over the past three years.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Mar 29Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₩14,050, the stock trades at a trailing P/E ratio of 40x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 51% over the past three years.Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₩13,600, the stock trades at a trailing P/E ratio of 38.7x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 54% over the past three years.Valuation Update With 7 Day Price Move • Feb 24Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩10,350, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 4.0% over the past three years.Reported Earnings • Feb 20Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: EPS: ₩165 (up from ₩82.00 in 2Q 2021). Revenue: ₩6.53b (up 15% from 2Q 2021). Net income: ₩1.37b (up 119% from 2Q 2021). Profit margin: 21% (up from 11% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 19%. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 11% per year.Reported Earnings • Nov 19First quarter 2022 earnings released: ₩37.00 loss per share (vs ₩45.00 loss in 1Q 2021)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2022 results: Revenue: ₩3.98b (up 23% from 1Q 2021). Net loss: ₩311.8m (loss narrowed 8.5% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Oct 20Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩10,200, the stock trades at a trailing P/E ratio of 32.7x. Average trailing P/E is 20x in the Chemicals industry in South Korea. Total returns to shareholders of 14% over the past three years.Valuation Update With 7 Day Price Move • Aug 17Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩10,000, the stock trades at a trailing P/E ratio of 49.2x. Average trailing P/E is 20x in the Chemicals industry in South Korea. Total loss to shareholders of 20% over the past three years.Valuation Update With 7 Day Price Move • Jul 29Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩11,750, the stock trades at a trailing P/E ratio of 57.9x. Average trailing P/E is 21x in the Chemicals industry in South Korea. Total returns to shareholders of 4.8% over the past three years.Upcoming Dividend • Jun 22Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 June 2021. Payment date: 15 October 2021. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (2.1%). Lower than average of industry peers (1.4%).Valuation Update With 7 Day Price Move • Jun 09Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩11,750, the stock trades at a trailing P/E ratio of 57.9x. Average trailing P/E is 21x in the Chemicals industry in South Korea. Total loss to shareholders of 17% over the past three years.Reported Earnings • May 22Third quarter 2021 earnings released: EPS ₩98.00 (vs ₩148 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₩8.20b (down 21% from 3Q 2020). Net income: ₩747.6m (down 35% from 3Q 2020). Profit margin: 9.1% (down from 11% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • May 04Investor sentiment improved over the past weekAfter last week's 45% share price gain to ₩13,300, the stock trades at a trailing P/E ratio of 53.6x. Average trailing P/E is 20x in the Chemicals industry in South Korea. Total loss to shareholders of 15% over the past three years.분석 기사 • Mar 30HyosungONBCo.Ltd (KOSDAQ:097870) Has A Rock Solid Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Mar 12A Look At The Intrinsic Value Of HyosungONBCo.,Ltd (KOSDAQ:097870)How far off is HyosungONBCo.,Ltd ( KOSDAQ:097870 ) from its intrinsic value? Using the most recent financial data...분석 기사 • Feb 22Are HyosungONBCo.Ltd's (KOSDAQ:097870) Statutory Earnings A Good Guide To Its Underlying Profitability?Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...Reported Earnings • Feb 20Second quarter 2021 earnings released: EPS ₩82.00 (vs ₩42.00 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₩5.70b (up 7.6% from 2Q 2020). Net income: ₩626.2m (up 90% from 2Q 2020). Profit margin: 11% (up from 6.2% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.분석 기사 • Feb 14How Well Is HyosungONBCo.Ltd (KOSDAQ:097870) Allocating Its Capital?When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...분석 기사 • Jan 24How Much Did HyosungONBCo.Ltd's(KOSDAQ:097870) Shareholders Earn From Share Price Movements Over The Last Five Years?HyosungONBCo.,Ltd ( KOSDAQ:097870 ) shareholders should be happy to see the share price up 18% in the last quarter. But...Is New 90 Day High Low • Jan 14New 90-day high: ₩8,430The company is up 11% from its price of ₩7,620 on 16 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 36% over the same period.분석 기사 • Jan 03Does The Market Have A Low Tolerance For HyosungONBCo.,Ltd's (KOSDAQ:097870) Mixed Fundamentals?HyosungONBCo.Ltd (KOSDAQ:097870) has had a rough three months with its share price down 5.0%. We, however decided to...분석 기사 • Dec 13HyosungONBCo.Ltd (KOSDAQ:097870) Seems To Use Debt Rather SparinglyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Nov 20First quarter 2021 earnings released: ₩45.00 loss per shareThe company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: ₩3.23b (down 5.6% from 1Q 2020). Net loss: ₩340.6m (loss narrowed 16% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Oct 27New 90-day low: ₩6,970The company is down 2.0% from its price of ₩7,110 on 29 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 19% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 A097870 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: A097870 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장HyosungONBCo.Ltd 배당 수익률 vs 시장A097870의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (A097870)0%시장 하위 25% (KR)1.3%시장 상위 25% (KR)4.2%업계 평균 (Chemicals)1.6%분석가 예측 (A097870) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 A097870 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 A097870 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: A097870 KR 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: A097870 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YKR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/15 10:21종가2026/08/14 00:00수익2026/03/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스HyosungONBCo.,Ltd는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Hong-Sik JeongLS Securities Co., Ltd.Tae Gi HaSK Securities Co., Ltd.
Upcoming Dividend • Jun 22Upcoming dividend of ₩100.00 per share at 1.1% yieldEligible shareholders must have bought the stock before 29 June 2023. Payment date: 12 October 2023. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.2%). Lower than average of industry peers (1.5%).
Upcoming Dividend • Jun 22Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 June 2021. Payment date: 15 October 2021. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (2.1%). Lower than average of industry peers (1.4%).
공고 • 13hHyosungONBCo.,Ltd, Annual General Meeting, Sep 29, 2026HyosungONBCo.,Ltd, Annual General Meeting, Sep 29, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 46, yuseong-daero 1596beon-gil, yuseong-gu, daejeon South Korea
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩4,185, the stock trades at a trailing P/E ratio of 51.1x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total loss to shareholders of 47% over the past three years.
Buy Or Sell Opportunity • Jun 12Now 22% overvaluedOver the last 90 days, the stock has fallen 21% to ₩5,180. The fair value is estimated to be ₩4,260, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 14% over the last 3 years. Earnings per share has declined by 8.4%.
Reported Earnings • Feb 22Second quarter 2026 earnings released: ₩60.00 loss per share (vs ₩100.00 profit in 2Q 2025)Second quarter 2026 results: ₩60.00 loss per share (down from ₩100.00 profit in 2Q 2025). Revenue: ₩4.22b (down 32% from 2Q 2025). Net loss: ₩472.0m (down 160% from profit in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
New Risk • Feb 22New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 33% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.2% net profit margin). Market cap is less than US$100m (₩49.2b market cap, or US$34.0m).
New Risk • Nov 29New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 12% Last year net profit margin: 17% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (12% net profit margin). Market cap is less than US$100m (₩48.1b market cap, or US$32.8m).
분석 기사 • Sep 23Some Investors May Be Willing To Look Past HyosungONBCo.Ltd's (KOSDAQ:097870) Soft EarningsThe market for HyosungONBCo.,Ltd's ( KOSDAQ:097870 ) shares didn't move much after it posted weak earnings recently...
Reported Earnings • Sep 18Full year 2025 earnings released: EPS: ₩354 (vs ₩548 in FY 2024)Full year 2025 results: EPS: ₩354 (down from ₩548 in FY 2024). Revenue: ₩24.4b (down 13% from FY 2024). Net income: ₩2.81b (down 37% from FY 2024). Profit margin: 12% (down from 16% in FY 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
공고 • Aug 15HyosungONBCo.,Ltd, Annual General Meeting, Sep 29, 2025HyosungONBCo.,Ltd, Annual General Meeting, Sep 29, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 46, yuseong-daero 1596beon-gil, yuseong-gu, daejeon South Korea
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩6,250, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total loss to shareholders of 53% over the past three years.
분석 기사 • Mar 28HyosungONBCo.Ltd's (KOSDAQ:097870) Returns On Capital Are Heading HigherWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...
Reported Earnings • Feb 20Second quarter 2025 earnings released: EPS: ₩100.00 (vs ₩273 in 2Q 2024)Second quarter 2025 results: EPS: ₩100.00 (down from ₩273 in 2Q 2024). Revenue: ₩6.21b (down 18% from 2Q 2024). Net income: ₩788.5m (down 65% from 2Q 2024). Profit margin: 13% (down from 30% in 2Q 2024). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
New Risk • Jan 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩54.6b market cap, or US$37.8m).
분석 기사 • Jan 03Why Investors Shouldn't Be Surprised By HyosungONBCo.,Ltd's (KOSDAQ:097870) 28% Share Price SurgeHyosungONBCo.,Ltd ( KOSDAQ:097870 ) shares have had a really impressive month, gaining 28% after a shaky period...
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩59.0b market cap, or US$41.1m).
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improves as stock rises 44%After last week's 44% share price gain to ₩7,480, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total loss to shareholders of 5.3% over the past three years.
분석 기사 • Sep 26HyosungONBCo.Ltd's (KOSDAQ:097870) Profits May Not Reveal Underlying IssuesThe recent earnings posted by HyosungONBCo.,Ltd ( KOSDAQ:097870 ) were solid, but the stock didn't move as much as we...
Reported Earnings • Sep 20Full year 2024 earnings released: EPS: ₩548 (vs ₩155 in FY 2023)Full year 2024 results: EPS: ₩548 (up from ₩155 in FY 2023). Revenue: ₩28.1b (down 5.4% from FY 2023). Net income: ₩4.49b (up 255% from FY 2023). Profit margin: 16% (up from 4.3% in FY 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
공고 • Aug 15HyosungONBCo.,Ltd, Annual General Meeting, Sep 27, 2024HyosungONBCo.,Ltd, Annual General Meeting, Sep 27, 2024, at 10:00 Tokyo Standard Time. Location: conference room, 46, yuseong-daero 1596beon-gil, yuseong-gu, daejeon South Korea
분석 기사 • Aug 06Is HyosungONBCo.Ltd (KOSDAQ:097870) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩5,860, the stock trades at a trailing P/E ratio of 9.2x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 52% over the past three years.
Reported Earnings • Feb 19Second quarter 2024 earnings released: EPS: ₩273 (vs ₩106 in 2Q 2023)Second quarter 2024 results: EPS: ₩273 (up from ₩106 in 2Q 2023). Revenue: ₩7.53b (up 29% from 2Q 2023). Net income: ₩2.24b (up 159% from 2Q 2023). Profit margin: 30% (up from 15% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has fallen by 2% per year.
Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩8,400, the stock trades at a trailing P/E ratio of 41x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 10% over the past three years.
Reported Earnings • Nov 19First quarter 2024 earnings released: ₩48.00 loss per share (vs ₩98.00 loss in 1Q 2023)First quarter 2024 results: ₩48.00 loss per share (improved from ₩98.00 loss in 1Q 2023). Revenue: ₩3.47b (up 17% from 1Q 2023). Net loss: ₩393.2m (loss narrowed 51% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 21Full year 2023 earnings released: EPS: ₩155 (vs ₩464 in FY 2022)Full year 2023 results: EPS: ₩155 (down from ₩464 in FY 2022). Revenue: ₩29.7b (down 13% from FY 2022). Net income: ₩1.27b (down 67% from FY 2022). Profit margin: 4.3% (down from 11% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Upcoming Dividend • Jun 22Upcoming dividend of ₩100.00 per share at 1.1% yieldEligible shareholders must have bought the stock before 29 June 2023. Payment date: 12 October 2023. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.2%). Lower than average of industry peers (1.5%).
Reported Earnings • May 18Third quarter 2023 earnings released: EPS: ₩66.00 (vs ₩105 in 3Q 2022)Third quarter 2023 results: EPS: ₩66.00 (down from ₩105 in 3Q 2022). Revenue: ₩9.05b (down 4.6% from 3Q 2022). Net income: ₩542.4m (down 37% from 3Q 2022). Profit margin: 6.0% (down from 9.1% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩9,540, the stock trades at a trailing P/E ratio of 25x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 59% over the past three years.
Reported Earnings • Feb 19Second quarter 2023 earnings released: EPS: ₩106 (vs ₩165 in 2Q 2022)Second quarter 2023 results: EPS: ₩106 (down from ₩165 in 2Q 2022). Revenue: ₩5.83b (down 11% from 2Q 2022). Net income: ₩864.6m (down 37% from 2Q 2022). Profit margin: 15% (down from 21% in 2Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 19First quarter 2023 earnings released: ₩98.00 loss per share (vs ₩37.00 loss in 1Q 2022)First quarter 2023 results: ₩98.00 loss per share (further deteriorated from ₩37.00 loss in 1Q 2022). Revenue: ₩2.96b (down 26% from 1Q 2022). Net loss: ₩806.3m (loss widened 159% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩8,190, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 10% over the past three years.
Reported Earnings • Sep 23Full year 2022 earnings released: EPS: ₩464 (vs ₩306 in FY 2021)Full year 2022 results: EPS: ₩464 (up from ₩306 in FY 2021). Revenue: ₩34.0b (up 13% from FY 2021). Net income: ₩3.86b (up 62% from FY 2021). Profit margin: 11% (up from 7.9% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩12,100, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 73% over the past three years.
Valuation Update With 7 Day Price Move • Jul 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩9,270, the stock trades at a trailing P/E ratio of 25.4x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 19% over the past three years.
Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₩12,150, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 37% over the past three years.
Reported Earnings • May 22Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: EPS: ₩105 (up from ₩98.00 in 3Q 2021). Revenue: ₩9.49b (up 16% from 3Q 2021). Net income: ₩863.1m (up 16% from 3Q 2021). Profit margin: 9.1% (in line with 3Q 2021). Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 19%. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩11,950, the stock trades at a trailing P/E ratio of 34x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 42% over the past three years.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Mar 29Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₩14,050, the stock trades at a trailing P/E ratio of 40x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 51% over the past three years.
Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₩13,600, the stock trades at a trailing P/E ratio of 38.7x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 54% over the past three years.
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩10,350, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 4.0% over the past three years.
Reported Earnings • Feb 20Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: EPS: ₩165 (up from ₩82.00 in 2Q 2021). Revenue: ₩6.53b (up 15% from 2Q 2021). Net income: ₩1.37b (up 119% from 2Q 2021). Profit margin: 21% (up from 11% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 19%. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 11% per year.
Reported Earnings • Nov 19First quarter 2022 earnings released: ₩37.00 loss per share (vs ₩45.00 loss in 1Q 2021)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2022 results: Revenue: ₩3.98b (up 23% from 1Q 2021). Net loss: ₩311.8m (loss narrowed 8.5% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Oct 20Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩10,200, the stock trades at a trailing P/E ratio of 32.7x. Average trailing P/E is 20x in the Chemicals industry in South Korea. Total returns to shareholders of 14% over the past three years.
Valuation Update With 7 Day Price Move • Aug 17Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩10,000, the stock trades at a trailing P/E ratio of 49.2x. Average trailing P/E is 20x in the Chemicals industry in South Korea. Total loss to shareholders of 20% over the past three years.
Valuation Update With 7 Day Price Move • Jul 29Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩11,750, the stock trades at a trailing P/E ratio of 57.9x. Average trailing P/E is 21x in the Chemicals industry in South Korea. Total returns to shareholders of 4.8% over the past three years.
Upcoming Dividend • Jun 22Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 June 2021. Payment date: 15 October 2021. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (2.1%). Lower than average of industry peers (1.4%).
Valuation Update With 7 Day Price Move • Jun 09Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩11,750, the stock trades at a trailing P/E ratio of 57.9x. Average trailing P/E is 21x in the Chemicals industry in South Korea. Total loss to shareholders of 17% over the past three years.
Reported Earnings • May 22Third quarter 2021 earnings released: EPS ₩98.00 (vs ₩148 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₩8.20b (down 21% from 3Q 2020). Net income: ₩747.6m (down 35% from 3Q 2020). Profit margin: 9.1% (down from 11% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • May 04Investor sentiment improved over the past weekAfter last week's 45% share price gain to ₩13,300, the stock trades at a trailing P/E ratio of 53.6x. Average trailing P/E is 20x in the Chemicals industry in South Korea. Total loss to shareholders of 15% over the past three years.
분석 기사 • Mar 30HyosungONBCo.Ltd (KOSDAQ:097870) Has A Rock Solid Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
분석 기사 • Mar 12A Look At The Intrinsic Value Of HyosungONBCo.,Ltd (KOSDAQ:097870)How far off is HyosungONBCo.,Ltd ( KOSDAQ:097870 ) from its intrinsic value? Using the most recent financial data...
분석 기사 • Feb 22Are HyosungONBCo.Ltd's (KOSDAQ:097870) Statutory Earnings A Good Guide To Its Underlying Profitability?Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...
Reported Earnings • Feb 20Second quarter 2021 earnings released: EPS ₩82.00 (vs ₩42.00 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₩5.70b (up 7.6% from 2Q 2020). Net income: ₩626.2m (up 90% from 2Q 2020). Profit margin: 11% (up from 6.2% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
분석 기사 • Feb 14How Well Is HyosungONBCo.Ltd (KOSDAQ:097870) Allocating Its Capital?When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...
분석 기사 • Jan 24How Much Did HyosungONBCo.Ltd's(KOSDAQ:097870) Shareholders Earn From Share Price Movements Over The Last Five Years?HyosungONBCo.,Ltd ( KOSDAQ:097870 ) shareholders should be happy to see the share price up 18% in the last quarter. But...
Is New 90 Day High Low • Jan 14New 90-day high: ₩8,430The company is up 11% from its price of ₩7,620 on 16 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 36% over the same period.
분석 기사 • Jan 03Does The Market Have A Low Tolerance For HyosungONBCo.,Ltd's (KOSDAQ:097870) Mixed Fundamentals?HyosungONBCo.Ltd (KOSDAQ:097870) has had a rough three months with its share price down 5.0%. We, however decided to...
분석 기사 • Dec 13HyosungONBCo.Ltd (KOSDAQ:097870) Seems To Use Debt Rather SparinglyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Nov 20First quarter 2021 earnings released: ₩45.00 loss per shareThe company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: ₩3.23b (down 5.6% from 1Q 2020). Net loss: ₩340.6m (loss narrowed 16% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Oct 27New 90-day low: ₩6,970The company is down 2.0% from its price of ₩7,110 on 29 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 19% over the same period.